{"title":"Plasma lipoprotein (a) and long-term all-cause mortality in myocardial infarction survivors: a cohort study.","authors":"Timo Schmitz, Jakob Linseisen, Christa Meisinger","doi":"10.1186/s12944-026-03111-0","DOIUrl":"https://doi.org/10.1186/s12944-026-03111-0","url":null,"abstract":"<p><strong>Background: </strong>Elevated concentrations of lipoprotein (a) [Lp(a)] are a well-established risk factor for the development of coronary artery diseases and acute myocardial infarction (AMI). The objective of the present study was to analyze the association between plasma concentrations of Lp(a) and long-term all-cause mortality among individuals with a history of hospitalized AMI.</p><p><strong>Methods: </strong>The analysis was based on data from 617 patients with a history of AMI recruited by the Augsburg Myocardial Infarction Registry and examined in a follow-up visit within the scope of the KORA Family Heart Study in 1996 and 1997 (median time between AMI and follow-up examination: 6.2 years). In addition, 545 siblings of the patients were included in the study and underwent examination. The examination included venous blood sampling and a patient interview. Plasma concentrations of Lp(a) were measured using a latex-enhanced immunoassay. Information on vital status was obtained in November 2025 in a comprehensive mortality follow-up [median follow-up time: 18.2 years (IQR: 10.8-27.7)]. Follow-up time was calculated from examination date to date of death or censoring. Kaplan-Meier curves were used to display estimated survival probability of Lp(a) high (≥ 50 mg/dL) and low (< 50 mg/dL) group. Multivariable adjusted Cox regression models with restricted cubic splines were used to analyze the association between Lp(a) concentrations and long-term all-cause mortality after AMI.</p><p><strong>Results: </strong>Kaplan-Meier curves and log rank test (p value: 0.273) demonstrated no differences in long-term all-cause mortality between the high and low Lp(a) group. The multivariable adjusted Cox regression confirmed the absence of a significant association between Lp(a) concentrations and total mortality (HR for the high Lp(a) group: 1.04, 95%CI: 0.84-1.28, p value: 0.734). Several sensitivity analyses, including a mixed model on a sample including siblings of the AMI patients (HR for the high Lp(a) group: 1.09) and a more thoroughly adjusted model including additional potential confounders confirmed the results of the main model.</p><p><strong>Conclusions: </strong>In this study, no association between elevated Lp(a) and long-term mortality was detected. Due to the observational character of the study, no conclusions about treatment of patients with elevated Lp(a) can be made and results must be regarded as exploratory and hypothesis generating.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13769197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wann Jia Loh, Mon Hnin Tun, Brenda Shak, Soon Kieng Phua, Geraldine Lim, Carolyn Yap, Joan Khoo, Troy Puar, Chew Kiat Heng, Roger Foo, Gerald F Watts, Rinkoo Dalan, Tar Choon Aw
{"title":"Correction: Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers.","authors":"Wann Jia Loh, Mon Hnin Tun, Brenda Shak, Soon Kieng Phua, Geraldine Lim, Carolyn Yap, Joan Khoo, Troy Puar, Chew Kiat Heng, Roger Foo, Gerald F Watts, Rinkoo Dalan, Tar Choon Aw","doi":"10.1186/s12944-026-03067-1","DOIUrl":"10.1186/s12944-026-03067-1","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13749782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Li Li, Chengfeng Fu, Ruqi Zhang, Minyan Zhang, Xinrui Tian
{"title":"Integrating machine learning and traditional statistics to evaluate the Uric acid-to-HDL cholesterol ratio for identification of prevalent COPD in older adults.","authors":"Li Li, Chengfeng Fu, Ruqi Zhang, Minyan Zhang, Xinrui Tian","doi":"10.1186/s12944-026-03102-1","DOIUrl":"10.1186/s12944-026-03102-1","url":null,"abstract":"<p><strong>Background: </strong>The uric acid-to-high-density lipoprotein cholesterol ratio (UHR) is a novel inflammatory and metabolic biomarker, but its association with chronic obstructive pulmonary disease (COPD) in older adults remains unclear. This study investigated the relationship between UHR and COPD prevalence among adults aged ≥ 60 years.</p><p><strong>Methods: </strong>This cross-sectional study analyzed 5,277 participants aged ≥ 60 years from NHANES 2013-2018. Weighted multivariable logistic regression estimated the UHR-COPD association. Restricted cubic spline (RCS) analysis characterized the dose-response relationship, and receiver operating characteristic (ROC) curves evaluated model performance. Subgroup, sensitivity, and machine learning analyses were conducted. Variables with missingness of 20% or higher were not imputed and were instead examined in complete-case analyses.</p><p><strong>Results: </strong>Of 5,277 participants, 404 (7.7%) had COPD. Elevated UHR was independently associated with higher COPD prevalence. In the fully adjusted model, each standard deviation (SD) increase in UHR corresponded to 23% higher odds (OR 1.23; 95% CI 1.05-1.44; P = 0.015). The highest versus lowest UHR quartile showed significantly higher risk (OR 1.71; 95% CI 1.09-2.68; P for trend = 0.019). RCS confirmed a linear dose-response relationship (P for non-linearity = 0.449). The model had good discrimination (AUC = 0.785). Adding UHR to 15 conventional predictors gave a small but statistically detectable increment in discrimination (AUC 0.784 to 0.788; DeLong P = 0.049), although the reclassification gains were small. After further adjustment for alcohol, the top-quartile association (OR 2.201, 95% CI 1.202 to 4.031; P = 0.018) and the quartile trend (P = 0.012) were retained, whereas the per-standard-deviation estimate was attenuated (OR 1.241, 95% CI 0.980 to 1.571; P = 0.085).</p><p><strong>Conclusions: </strong>Elevated UHR is associated with a higher prevalence of COPD in older adults. UHR may serve as a low-cost, routinely measurable marker to aid in the identification of prevalent, physician-diagnosed COPD in geriatric care. Because COPD status was ascertained at a single survey time point in a cross-sectional analysis, no prospective-screening inference is intended.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13741772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuhang Yang, Yunjie Zhang, Jianrong Ji, Chao Song, Shiping Wang, Zaiqiang Liu, Xiaopeng Li, Yuanjiang Min, Xihao Tang, Jianxun Jiang, Guixuan Li, Mengyuan Fan, Qinfei Yang, Shizheng Hui, Jun Yuan, Guang Yang, Yandong Liu, Jun Li
{"title":"Correction: Dyslipidemia is associated with abdominal fat depots but not with bone mineral density and muscle fat infiltration.","authors":"Yuhang Yang, Yunjie Zhang, Jianrong Ji, Chao Song, Shiping Wang, Zaiqiang Liu, Xiaopeng Li, Yuanjiang Min, Xihao Tang, Jianxun Jiang, Guixuan Li, Mengyuan Fan, Qinfei Yang, Shizheng Hui, Jun Yuan, Guang Yang, Yandong Liu, Jun Li","doi":"10.1186/s12944-026-03082-2","DOIUrl":"10.1186/s12944-026-03082-2","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13663036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Circulating sphingomyelins and mortality in a community-based Korean cohort: the Korean Genome and epidemiology study.","authors":"Soon Sung Kwon, John Hoon Rim, Yonggeun Cho, Jikyo Lee, Kwang Seob Lee, Sang-Guk Lee, Jong-Baeck Lim","doi":"10.1186/s12944-026-03091-1","DOIUrl":"https://doi.org/10.1186/s12944-026-03091-1","url":null,"abstract":"<p><strong>Background: </strong>Circulating sphingomyelins (SMs) have been proposed as biomarkers of mortality and cardiovascular risk, but findings have varied across populations. We aimed to evaluate the associations in a community-based Korean cohort.</p><p><strong>Methods: </strong>This cohort study included 2,434 participants from the Ansan-Ansung cohort of the Korean Genome and Epidemiology Study. Seven SM species were measured at the 2005-2006 examination, and mortality data were linked through December 2024. Associations with all-cause, cardiovascular, and non-cardiovascular mortality and the composite cardiovascular outcome were examined using Cox proportional hazards models adjusted for demographic, lifestyle, clinical and laboratory factors. Multiple testing was addressed using the Benjamini-Hochberg procedure across 28 tests within each adjustment model.</p><p><strong>Results: </strong>During a median follow-up of 18.5 years, 426 deaths occurred, including 79 cardiovascular deaths. In the fully adjusted model, higher SM 16:0 levels were nominally associated with all-cause mortality (hazard ratio 1.70; 95% CI, 1.07-2.70; P = 0.025), but the association was not statistically significant after correction for multiple testing. None of the seven SM species were significantly associated with all-cause, cardiovascular, or non-cardiovascular mortality or with the composite cardiovascular outcome after correction for multiple testing.</p><p><strong>Conclusions: </strong>In this community-based Korean cohort, circulating SMs were not significantly associated with mortality or cardiovascular outcomes. This suggests that the prognostic relevance of circulating SMs may be limited and may vary according to population characteristics.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13718081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: Dyslipidemia and metabolic syndrome in childhood-onset systemic lupus erythematosus: is it time to screen?","authors":"Sirin Nuntasri, Sirirat Charuvanij, Kraisoon Lomjansook, Puthita Saengpanit, Kwanjai Chotipanang, Maynart Sukharomana","doi":"10.1186/s12944-026-03061-7","DOIUrl":"10.1186/s12944-026-03061-7","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Huidan Liu, Kan Wang, Yujie Ren, Xuefang Hu, Mian Li, Tiange Wang, Min Xu, Jieli Lu, Yufang Bi, Yu Xu
{"title":"Correction: Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.","authors":"Huidan Liu, Kan Wang, Yujie Ren, Xuefang Hu, Mian Li, Tiange Wang, Min Xu, Jieli Lu, Yufang Bi, Yu Xu","doi":"10.1186/s12944-026-03060-8","DOIUrl":"10.1186/s12944-026-03060-8","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linus Haberbosch, Andrea Baessler, Ulrike de Ruiter, David Sinning, Julius L Katzmann, Stephanie Könemann, Ulrike Schatz, Knut Mai, Ursula Kassner, Thomas Bobbert
{"title":"Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study.","authors":"Linus Haberbosch, Andrea Baessler, Ulrike de Ruiter, David Sinning, Julius L Katzmann, Stephanie Könemann, Ulrike Schatz, Knut Mai, Ursula Kassner, Thomas Bobbert","doi":"10.1186/s12944-026-03062-6","DOIUrl":"10.1186/s12944-026-03062-6","url":null,"abstract":"<p><strong>Background: </strong>Dyslipidaemia remains a leading cause of death in Germany despite an improving therapeutic landscape, with many patients not achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals. Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, is a recent addition to the therapeutic landscape with proven efficacy in randomised controlled trials; however, its use varies between centres. We aimed to assess the short-term, real-world effectiveness of bempedoic acid in lowering LDL-C levels in patients in Germany.</p><p><strong>Methods: </strong>This retrospective, observational study was conducted using data from patients with primary hypercholesterolaemia or mixed dyslipidaemia, collected before and approximately 3 months after initiating bempedoic acid in 7 specialised lipid outpatient clinics in Germany.</p><p><strong>Results: </strong>Data were analysed from a total of 641 patients, with a mean age (standard deviation [SD]) of 63.2 (11.3) years. The addition of bempedoic acid significantly reduced LDL-C levels from a mean of 133.6 mg/dL at baseline to 101.8 mg/dL after 3 months (p < 0.001). The mean within-patient LDL-C reduction was 31.8 mg/dL and the mean patient-level percentage change was -17.5%. Mean patient-level changes were -4.9% for HDL-C and -12.0% for total cholesterol; triglycerides did not change significantly. At 3 months, patients not receiving any lipid-lowering therapy (LLT) other than bempedoic acid had a mean patient-level LDL-C reduction of 27.1%; corresponding mean reductions were 23.7% with ezetimibe, 20.3% with PCSK9 inhibitor therapy, 9.0% with statin therapy and 6.1% with statin plus ezetimibe. Suspected adverse events were documented in 218/641 patients (34.0%), and 171/641 (26.7%) had discontinued bempedoic acid by follow-up. Myalgia was the most commonly reported adverse event in patients discontinuing treatment (75 cases).</p><p><strong>Conclusions: </strong>Findings from this real-world, multicentre study conducted in Germany show that bempedoic acid may present an effective treatment option for patients with hypercholesterolaemia who are already receiving LLT, in addition to being an effective option for patients not receiving/tolerating other LLTs. The magnitude of LDL-C reduction differed across background treatment strategies, while suspected adverse events and treatment discontinuation were common in this specialist-care cohort.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A cardiometabolic risk phenotype index integrating insulin resistance, systemic inflammation, and psychological burden for mortality risk stratification in metabolic dysfunction-associated steatotic liver disease: an exploratory longitudinal analysis of a nationally representative cohort.","authors":"Yan Chen, Kailing Xie, Ningkun Xiao, Haonan Ju, Qingzhi Zhou, Xin Zhao","doi":"10.1186/s12944-026-03048-4","DOIUrl":"10.1186/s12944-026-03048-4","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is being increasingly recognized as a systemic cardiometabolic disorder rather than a liver-limited condition. However, the combined association of insulin resistance, systemic inflammation, and depressive symptoms with mortality remains unclear. Therefore, we developed an insulin resistance-systemic inflammation-psychological burden (ISP) index to evaluate its associations with all-cause mortality (ACM) and cardiovascular mortality (CVM).</p><p><strong>Methods: </strong>We analyzed data from 3,187 adults with MASLD in the 2005-2018 National Health and Nutrition Examination Survey. A random forest model based on mean decrease in accuracy was used to select representative markers from six insulin resistance surrogates and five systemic inflammation indices, which were combined with the PHQ-9 score to construct the ISP index. Weighted Kaplan-Meier and Cox analyses, restricted cubic splines, subgroup and sensitivity analyses, and interpretable machine learning with 5-fold cross-validation were performed.</p><p><strong>Results: </strong>During a median 8.25-year follow-up, 382 deaths occurred, including 114 cardiovascular deaths. The metabolic score for insulin resistance (METS-IR) and systemic inflammation response index (SIRI) were selected and combined with the PHQ-9 score to construct the ISP index. In fully adjusted Cox models, the highest ISP tertile was associated with higher risks of both ACM (HR = 1.63, 95% CI: 1.12-2.38) and CVM (HR = 2.88, 95% CI: 1.36‒6.10) compared with the lowest tertile. Eight ISP-based machine-learning models were internally evaluated using 5-fold cross-validation, with the GBM model yielding 10-year AUCs of 0.869 for ACM and 0.883 for CVM. SHAP analysis of the GBM model revealed that the ISP index ranked second in feature importance after age.</p><p><strong>Conclusions: </strong>The ISP index was positively associated with the risks of ACM and CVM among individuals with MASLD. However, because the ISP index was constructed and internally evaluated within the same sample, its apparent predictive performance may be optimistic owing to overfitting. Therefore, the ISP index requires external validation in larger, independent prospective cohorts.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic dysfunction-associated steatotic liver disease: pathogenic mechanisms and exercise-induced molecular adaptations.","authors":"Senlin Lei, Jiasheng Tao, Xiaoan Chen, Xianhui Li, Songwei Zhong","doi":"10.1186/s12944-026-03055-5","DOIUrl":"10.1186/s12944-026-03055-5","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic metabolic disorder that spans steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Although hepatic lipid overload is a central pathological feature, MASLD progression is driven by interconnected disturbances in lipid handling, mitochondrial function, oxidative stress, immune-inflammatory activation, programmed cell death, autophagy-lysosomal homeostasis, and gut-liver communication. This review critically synthesizes current evidence on the pathogenic mechanisms of MASLD and the molecular adaptations induced by exercise. We discuss how impaired lipid storage, oxidation, export, and detoxification interact with organelle stress, macrophage activation, inflammasome and cell-death signaling, defective autophagic clearance, and bidirectional gut-liver inputs to promote hepatocellular injury and fibrogenesis. We further examine how exercise modality, intensity, dose, and timing influence MASLD, and summarize evidence suggesting that exercise may enhance lipid mobilization and fatty acid oxidation, improve mitochondrial and autophagic quality control, restrain inflammatory and programmed cell-death pathways, and reshape gut-liver axis function. Defining disease-stage- and phenotype-specific responses, together with reliable metabolic and molecular biomarkers, will be essential for translating exercise-induced adaptations into individualized MASLD management.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}